The Spectrum of MORC2-Related Disorders: A Potential Link to Cockayne Syndrome.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
04 2023
Historique:
received: 08 11 2022
revised: 21 12 2022
accepted: 19 01 2023
medline: 28 3 2023
pubmed: 16 2 2023
entrez: 15 2 2023
Statut: ppublish

Résumé

Cockayne syndrome (CS) is a DNA repair disorder primarily associated with pathogenic variants in ERCC6 and ERCC8. As in other Mendelian disorders, there are a number of genetically unsolved CS cases. We ascertained five individuals with monoallelic pathogenic variants in MORC2, previously associated with three dominantly inherited phenotypes: an axonal form of Charcot-Marie-Tooth disease type 2Z; a syndrome of developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy; and a rare form of spinal muscular atrophy. One of these individuals bore a strong phenotypic resemblance to CS. We then identified monoallelic pathogenic MORC2 variants in three of five genetically unsolved individuals with a clinical diagnosis of CS. In total, we identified eight individuals with MORC2-related disorder, four of whom had clinical features strongly suggestive of CS. Our findings indicate that some forms of MORC2-related disorder have phenotypic similarities to CS, including features of accelerated aging. Unlike classic DNA repair disorders, MORC2-related disorder does not appear to be associated with a defect in transcription-coupled nucleotide excision repair and follows a dominant pattern of inheritance with variants typically arising de novo. Such de novo pathogenic variants present particular challenges with regard to both initial gene discovery and diagnostic evaluations. MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly and/or suspected DNA repair disorders. Future studies of MORC2 and its protein product, coupled with further phenotypic characterization, will help to optimize the diagnosis, understanding, and therapy of the associated disorders.

Sections du résumé

BACKGROUND
Cockayne syndrome (CS) is a DNA repair disorder primarily associated with pathogenic variants in ERCC6 and ERCC8. As in other Mendelian disorders, there are a number of genetically unsolved CS cases.
METHODS
We ascertained five individuals with monoallelic pathogenic variants in MORC2, previously associated with three dominantly inherited phenotypes: an axonal form of Charcot-Marie-Tooth disease type 2Z; a syndrome of developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy; and a rare form of spinal muscular atrophy.
RESULTS
One of these individuals bore a strong phenotypic resemblance to CS. We then identified monoallelic pathogenic MORC2 variants in three of five genetically unsolved individuals with a clinical diagnosis of CS. In total, we identified eight individuals with MORC2-related disorder, four of whom had clinical features strongly suggestive of CS.
CONCLUSIONS
Our findings indicate that some forms of MORC2-related disorder have phenotypic similarities to CS, including features of accelerated aging. Unlike classic DNA repair disorders, MORC2-related disorder does not appear to be associated with a defect in transcription-coupled nucleotide excision repair and follows a dominant pattern of inheritance with variants typically arising de novo. Such de novo pathogenic variants present particular challenges with regard to both initial gene discovery and diagnostic evaluations. MORC2 should be included in diagnostic genetic test panels targeting the evaluation of microcephaly and/or suspected DNA repair disorders. Future studies of MORC2 and its protein product, coupled with further phenotypic characterization, will help to optimize the diagnosis, understanding, and therapy of the associated disorders.

Identifiants

pubmed: 36791574
pii: S0887-8994(23)00011-5
doi: 10.1016/j.pediatrneurol.2023.01.011
pmc: PMC10098370
pii:
doi:

Substances chimiques

DNA Repair Enzymes EC 6.5.1.-
ERCC8 protein, human 0
Transcription Factors 0
MORC2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-86

Subventions

Organisme : FDA HHS
ID : R01 FD007483
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

Hum Mol Genet. 1999 Jul;8(7):1201-7
pubmed: 10369865
Biochim Biophys Acta. 2014 Feb;1843(2):316-26
pubmed: 24286864
Am J Hum Genet. 2020 Aug 6;107(2):352-363
pubmed: 32693025
Nat Genet. 2017 Jul;49(7):1035-1044
pubmed: 28581500
Genet Med. 2016 May;18(5):483-93
pubmed: 26204423
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cell Commun Signal. 2019 Dec 3;17(1):160
pubmed: 31796101
Am J Hum Genet. 1996 Feb;58(2):263-70
pubmed: 8571952
Hum Mutat. 2018 Sep;39(9):1284-1298
pubmed: 29858556
Orphanet J Rare Dis. 2021 Feb 3;16(1):63
pubmed: 33536051
Cell Rep. 2012 Dec 27;2(6):1657-69
pubmed: 23260667
Hum Mutat. 2010 Feb;31(2):113-26
pubmed: 19894250
Cell. 1996 Sep 6;86(5):811-22
pubmed: 8797827
Nature. 1993 May 13;363(6425):185-8
pubmed: 8483505
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Nat Genet. 1999 Oct;23(2):208-12
pubmed: 10508519
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Bioinformatics. 2015 Aug 15;31(16):2745-7
pubmed: 25851949
J Med Genet. 2018 May;55(5):329-343
pubmed: 29572252
Muscle Nerve. 2023 Feb;67(2):101-110
pubmed: 36190439
Dis Model Mech. 2021 Oct 1;14(10):
pubmed: 34695197
Brain. 2016 Jul;139(Pt 7):e40
pubmed: 27105897
Nature. 1990 Nov 1;348(6296):73-6
pubmed: 2234061
PLoS One. 2012;7(10):e46688
pubmed: 23056405
Am J Med Genet. 1992 Jan 1;42(1):68-84
pubmed: 1308368
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Brain. 2016 Jan;139(Pt 1):62-72
pubmed: 26497905
Neurogenetics. 2022 Oct;23(4):271-274
pubmed: 35920923
Am J Hum Genet. 1997 Feb;60(2):320-9
pubmed: 9012405
Front Cell Neurosci. 2022 Jun 03;16:896854
pubmed: 35722617
Brain. 2017 Apr 1;140(4):e21
pubmed: 28334961
Nature. 1984 Aug 2-8;310(5976):425-9
pubmed: 6462228
Eur J Med Genet. 2021 Jan;64(1):104105
pubmed: 33227433
Genome Med. 2021 Feb 22;13(1):31
pubmed: 33618777
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669

Auteurs

Seth A Stafki (SA)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Johnnie Turner (J)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Hannah R Littel (HR)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Christine C Bruels (CC)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Don Truong (D)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Ursula Knirsch (U)

Neuromuscular Center Zürich and Department of Pediatric Neurology, University Children's Hospital Zürich, University of Zürich, Zürich, Switzerland.

Georg M Stettner (GM)

Neuromuscular Center Zürich and Department of Pediatric Neurology, University Children's Hospital Zürich, University of Zürich, Zürich, Switzerland.

Urs Graf (U)

Institute of Medical Molecular Genetics (IMMG), University of Zürich, Zürich, Switzerland.

Wolfgang Berger (W)

Institute of Medical Molecular Genetics (IMMG), University of Zürich, Zürich, Switzerland; Neuroscience Center Zurich (NCZ), University and ETH Zürich, Zürich, Switzerland; Zürich Center for Integrative Human Physiology (ZIHP), University of Zürich, Zürich, Switzerland.

Maria Kinali (M)

Department of Brain Sciences, Imperial College London and Portland Hospital HCA International, London, United Kingdom.

Heinz Jungbluth (H)

Evelina Children's Hospital and King's College London, University of Manchester, London, United Kingdom.

Christina A Pacak (CA)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota.

Jayne Hughes (J)

Amy and Friends Cockayne Syndrome/Trichothiodystrophy Support, Wirral, United Kingdom.

Amytice Mirchi (A)

Departments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada.

Alexa Derksen (A)

Departments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada.

Catherine Vincent-Delorme (C)

Department of Clinical Genetics, Hôpital Jeanne de Flandre, CHU Lille, Lille, France.

Arjan F Theil (AF)

Department of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Geneviève Bernard (G)

Departments of Neurology and Neurosurgery and Pediatrics, McGill University, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada; Department of Human Genetics, McGill University, Montreal, Canada; Division of Medical Genetics, Department Specialized Medicine, McGill University Health Center, Montreal, Canada.

David Ellis (D)

South East Genomics Laboratory Hub, Guy's Hospital, London, United Kingdom.

Hiva Fassihi (H)

St. John's Institute of Dermatology, Rare Disease Centre, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.

Alan R Lehmann (AR)

Genome Damage and Stability Centre, University of Sussex, Brighton, United Kingdom.

Vincent Laugel (V)

Service de Pédiatrie 1, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Laboratoire de Génétique médicale, INSERM U1112, Institut de génétique médicale d'Alsace, Faculté de Médecine de Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Shehla Mohammed (S)

South East Thames Regional Genetics Service and Rare Diseases Centre Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Peter B Kang (PB)

Department of Neurology and Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, Minnesota; Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota. Electronic address: pkang@umn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH